201546, A Repeat-dose Study of Batefenterol/FF (GSK961081/GW685698) Compared With Placebo in the Treatment of COPD

Trial Profile

201546, A Repeat-dose Study of Batefenterol/FF (GSK961081/GW685698) Compared With Placebo in the Treatment of COPD

Completed
Phase of Trial: Phase II

Latest Information Update: 24 May 2017

At a glance

  • Drugs Batefenterol/fluticasone furoate (Primary) ; Salbutamol
  • Indications Chronic obstructive pulmonary disease
  • Focus Adverse reactions
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 24 May 2017 Primary endpoint (Change from baseline in 0-4 hours post-dose weighted mean heart rate (derived from 12-lead electrocardiogram [ECG]), at the end of the 6 weeks treatment) has been met, according to the results presented at the 113th International Conference of the American Thoracic Society.
    • 24 May 2017 Results presented at the 113th International Conference of the American Thoracic Society.
    • 29 Jul 2016 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top